PMID- 34497814
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210910
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent 
      in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
PG  - 712671
LID - 10.3389/fmed.2021.712671 [doi]
LID - 712671
AB  - Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class 
      of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose 
      reabsorption in the renal proximal tubule to promote glycosuria and reduce blood 
      glucose levels. SGLT2i has been clinically indicated for treating T2DM, with 
      numerous recent publications focussing on both primary and secondary prevention 
      of cardiovascular and renal events in Type 2 diabetic patients. The most recent 
      clinical trials showed that SGLT2i have moderately significant beneficial effects 
      on atherosclerotic major adverse cardiovascular events (MACE) in patients with 
      histories of atherosclerotic cardiovascular disease. In this review and analysis, 
      SGLT2i have however demonstrated clinically significant benefits in reducing 
      hospitalisation for heart failure and worsening of chronic kidney disease (CKD) 
      irrespective of pre-existing atherosclerotic cardiovascular disease or previous 
      heart failure history. A meta-analysis suggests that all SGLT2 inhibitors 
      demonstrated the therapeutic benefit on all-cause and cardiovascular mortality, 
      as shown in EMPAREG OUTCOME study with a significant decrease in myocardial 
      infarction, without increased stroke risk. All the above clinical trial recruited 
      type 2 diabetic patients. This article aims to postulate and review the possible 
      primary prevention role of SGLT2i in healthy individuals by reviewing the current 
      literature and provide a prospective overview. The emphasis will include primary 
      prevention of Type 2 Diabetes, Heart Failure, CKD, Hypertension, Obesity and 
      Dyslipidaemia in healthy individuals, whom are defined as healthy, low or 
      intermediate risks patients.
CI  - Copyright (c) 2021 Xu, Chandler, Wee, Ho, Affandi, Yang, Liao, Chen, Li, Reid and 
      Xiao.
FAU - Xu, Dan
AU  - Xu D
AD  - Faculty of Health Sciences, CCRE, Curtin School of Population Health, Curtin 
      University, Perth, WA, Australia.
AD  - Faculty of Health Sciences, Curtin Medical School, Curtin University, Perth, WA, 
      Australia.
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Chandler, Owain
AU  - Chandler O
AD  - Faculty of Health Sciences, Curtin Medical School, Curtin University, Perth, WA, 
      Australia.
FAU - Wee, Cleo
AU  - Wee C
AD  - Faculty of Health Sciences, Curtin Medical School, Curtin University, Perth, WA, 
      Australia.
FAU - Ho, Chau
AU  - Ho C
AD  - Faculty of Health Sciences, CCRE, Curtin School of Population Health, Curtin 
      University, Perth, WA, Australia.
FAU - Affandi, Jacquita S
AU  - Affandi JS
AD  - Faculty of Health Sciences, CCRE, Curtin School of Population Health, Curtin 
      University, Perth, WA, Australia.
FAU - Yang, Daya
AU  - Yang D
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Department of Cardiology, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Liao, Xinxue
AU  - Liao X
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Department of Cardiology, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Department of Renal Medicine, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Li, Yanbing
AU  - Li Y
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Department of Endocrinology, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Reid, Christopher
AU  - Reid C
AD  - Faculty of Health Sciences, CCRE, Curtin School of Population Health, Curtin 
      University, Perth, WA, Australia.
FAU - Xiao, Haipeng
AU  - Xiao H
AD  - Department of Medical Education, First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Department of Endocrinology, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210823
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8419219
OTO - NOTNLM
OT  - SGLT2i inhibitor
OT  - cardioprotection
OT  - chronic diseases prevention
OT  - primary prevention
OT  - renoprotection
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/10 06:00
MHDA- 2021/09/10 06:01
PMCR- 2021/08/23
CRDT- 2021/09/09 06:52
PHST- 2021/05/21 00:00 [received]
PHST- 2021/07/23 00:00 [accepted]
PHST- 2021/09/09 06:52 [entrez]
PHST- 2021/09/10 06:00 [pubmed]
PHST- 2021/09/10 06:01 [medline]
PHST- 2021/08/23 00:00 [pmc-release]
AID - 10.3389/fmed.2021.712671 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Aug 23;8:712671. doi: 10.3389/fmed.2021.712671. 
      eCollection 2021.